References

Brighenti, F., S. Valtuena, N. Pellegrini, D. Ardigo and D. del Rio et al., 2005. Total antioxidant capacity of the diet is inversely and independently related to plasma concentration of high-sensitivity C-reactive protein in adult Italian subjects. Br. J. Nutr., 93: 619-625.
PubMed  |  

Cappuccio, F.P., P. Strazzullo, E. Farinaro and M. Trevisan, 1993. Uric acid metabolism and tubular sodium handling. JAMA, 270: 354-359.
PubMed  |  Direct Link  |  

Ceriello, A., 2006. Effects of gliclazide beyond metabolic control metabolism. Metabolism, 55: 10-15.
CrossRef  |  

Collier, A., H.H. Watson, A.W. Patrick, C.A. Ludlam and B.F. Clarke, 1989. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabetes Metab., 15: 420-425.
PubMed  |  Direct Link  |  

Dehghan, A., I. Kardys, M.P. de Maat, A.G. Uitterlinden and E.J. Sijbrands et al., 2007. Genetic variation, C-reactive protein levels and incidence of diabetes. Diabetes, 56: 872-878.
PubMed  |  Direct Link  |  

Deron, S.J., 2003. C-reactive Protein. 1st Edn., McGraw-Hill, New York, ISBN-13: 978-0071426428, Pages: 208.

Fava, D., M. Cassone-Faldetta, O. Laurenti, O. de Luca, A. Ghiselli and G. de Mattia, 2010. Gliclazide reduces oxidative stress in type 2 diabetes. Diabetic Med., 27: 1041-1048.

Hayden, M.R. and S.C. Tyagi, 2004. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome and type 2 diabetes mellitus: The urate redox shuttle. Nutr. Metab., Vol. 1. 10.1186/1743-7075-1-10

Heart Protection Study Collaborative Group, 2011. C-reactive protein concentration and the vascular benefits of statin therapy: An analysis of 20,536 patients in the heart protection study. Lancet, 377: 469-476.

Jennings, P.E., 2000. Vascular benefits of gliclazide beyond glycemic control. Metabolism, 49: 17-20.
CrossRef  |  

Lau, D.C., B. Dhillon, H. Yan, P.E. Szmitko and S. Verma, 2005. CRP increment due to rise in IL-6 produced predominantly by adipocytes. Am. J. Physiol. Heart Circ. Physiol., 288: H2031-H2041.

Nakagawa, T., H. Hu, S. Zharikov, K.R. Tuttle and R.A. Short et al., 2006. A causal role for uric acid in fructose-induced metabolic syndrome. Am. J. Physiol. Renal Physiol., 290: F625-F631.
CrossRef  |  PubMed  |  Direct Link  |  

Pepys, M.B. and G.M. Hirschfield, 2003. C-reactive protein: A critical update. J. Clin. Invest., 111: 1805-1812.
CrossRef  |  Direct Link  |  

Perticone, F., A. Sciacqua, M. Perticone, F. Arturi, P.E. Scarpino, M. Quero and G. Sesti, 2011. Hyperuricemia associated with several risk factors for cardiovascular disease and diabetes. Diabetic Care J. Pharmacol., 2: 201-205.

Pradhan, A.D., J.E. Manson, N. Rifai, J.E. Buring and P.M. Ridker, 2001. Creactive protein, interleukin 6 and risk of developing type 2 diabetes. J. Am. Med. Assoc., 286: 327-334.

Sultanpur, M.C., S. Satyanarayana and K. Deepa, 2011. Drug-to-drug interaction between fluvastatin gliclazide in animal models. Pharmacologia, 2: 201-205.
CrossRef  |  

Young, J. and A. Anwar, 2009. Metabollism of sulphonylureas. Curr. Diabetes Rev., 5: 252-258.